Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages 1303-1310

  Donker, Mila ^a   van Tienhoven, Geertjan ^b   Straver, Marieke E ^a   Meijnen, Philip ^a   van de Velde, Cornelis J H ^c   Mansel, Robert E ^d   Cataliotti, Luigi ^e   Westenberg, A Helen ^f   Klinkenbijl, Jean H G ^g   Orzalesi, Lorenzo ^e   Bouma, Willem H ^h   van der Mijle, Huub C J ⁱ   Nieuwenhuijzen, Grard A P ^j   Veltkamp, Sanne C ^k   Slaets, Leen ^l   Duez, Nicole J ^l   de Graaf, Peter W ^m   van Dalen, Thijs ⁿ   Marinelli, Andreas ^o   Rijna, Herman ^p   Snoj, Marko ^q   Bundred, Nigel J ^r   Merkus, Jos W S ^s   Belkacemi, Yazid ^t   Petignat, Patrick ^u   Schinagl, Dominic A X ^v   Coens, Corneel ^l   Messina, Carlo G M ^l   Bogaerts, Jan ^l   Rutgers, Emiel J T ^a   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f Institute for Radiation Oncology Arnhem   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h GELRE HOSPITALS   (Netherlands)

ⁱ NIJ SMELLINGHE HOSPITAL   (Netherlands)

^j CATHARINA HOSPITAL   (Netherlands)

^k AMSTELLAND HOSPITAL   (Netherlands)

^l EORTC DATA CENTER   (Belgium)

^m REINIER DE GRAAF HOSPITAL   (Netherlands)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o MEDICAL CENTER HAAGLANDEN   (Netherlands)

^p Infection and Immunology   (Netherlands)

^q INSTITUTE OF ONCOLOGY   (Slovenia)

^r MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^s HAGA HOSPITAL   (Netherlands)

^t CENTRE OSCAR LAMBRET   (France)

^u GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; PARTIAL MASTECTOMY; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; AXILLA; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPH NODE; LYMPHATIC METASTASIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SENTINEL LYMPH NODE BIOPSY; TUMOR RECURRENCE;

AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SENTINEL LYMPH NODE BIOPSY;

EID: 84908568065     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70460-7     Document Type: Article

References (30)

1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391-398.
2. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008, 34:1277-1284.
3. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006, 98:599-609.
4. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
5. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 2010, 28:3929-3936.
6. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010, 102:111-118.
7. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006, 95:279-293.
8. Deutsch M, Land S, Begovic M, Sharif S The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys 2008, 70:1020-1024.
9. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25:3657-3663.
10. Clinical practice guidelines in oncology, version 3 National Comprehensive Cancer Network (NCCN), (accessed Sept 1, 2013). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
11. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
12. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252:426-432.
13. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013, 14:297-305.
14. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014, 32:1365-1383.
15. Haffty BG, Hunt KK, Harris JR, Buchholz TA Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol 2011, 29:4479-4481.
16. Gur AS, Unal B, Ozbek U, et al. Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol 2010, 36:30-35.
17. Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008, 26:2093-2098.
18. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567-575.
19. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004, 22:97-101.
20. Hoebers FJ, Borger JH, Hart AA, Peterse JL, Th EJ, Lebesque JV Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer 2000, 88:1633-1642.
21. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010, 17:1854-1861.
22. Bourez RL, Rutgers EJ The European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group: quality control of surgical trials. Surg Oncol Clin N Am 2001, 10:807-819. ix.
23. Julien JP, Jassem J, Rutgers E Manual for Clinical Research in Breast Cancer 2004, EORTC Breast Cancer Cooperative Group, Greenwich Medical Media, London, UK. 5th edn.
24. Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol 2003, 68:233-240.
25. Osoba D, Rodrigues G, Myles J, Zee B, Pater J Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
26. Donker M, Rutgers E, van de Velde CJ, et al. Axillary lymph node dissection versus axillary radiotherapy: a detailed analysis of morbidity. Results from the EORTC 10981-22023 AMAROS trial. In: European Cancer Congress 2013 Presidential Sessions. Eur J Cancer 2013, 49(supp 3):S14. (abstr LBA30).
27. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992, 339:1245-1248.
28. Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study. J Cancer Surviv 2011, 5:62-72.
29. Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006, 15:1533-1550.
30. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg 2000, 232:1-7.